[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"anaplastic-throid-carcinoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:anaplastic-throid-carcinoma":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":5},"100581897","phase-1-clinical-study-of-nkg2d-car-nk-combined-with-pd-1-monoclonal-antibody-in-the-treatment-of-atc-100581897",false,"NCT06856278","Clinical Study of NKG2D CAR-NK Combined with PD-1 Monoclonal Antibody in the Treatment of ATC","Clinical Exploratory Study of NKG2D CAR-NK Combined with PD-1 Monoclonal Antibody in the Treatment of Anaplastic Thyroid Cancer (ATC)","Inclusion Criteria:\n\n1. Age 18-75 years (including boundary values), male or female.\n2. Be diagnosed with anaplastic thyroid cancer histopathologically with a measurable lesion≥1cm.\n3. Liver and kidney function is good, and can tolerate treatment.\n4. Be able to cooperate with the completion of treatment and follow-up work.\n5. No other systemic diseases, including other malignancies.\n\nExclusion Criteria:\n\n1. Need to breastfeed the baby or have fertility needs；\n2. Immune system diseases;\n3. Diseases of the blood system;\n4. Mental system diseases;\n5. Interstitial pneumonia, lung disease, etc.;\n6. Failure to follow rules of this study.","ALL","18 Years","75 Years",{"count":20,"type":21},30,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE1","PHASE2","The patients with anaplastic thyroid cancer were treated with CAR-NK immune cells combined with PD-1 monoclonal antibody, and the safety and tolerability of the patients were observed and evaluated.",[28],"Anaplastic Throid Carcinoma","NOT_YET_RECRUITING","2025-02-26",{"date":32,"type":33},"2025-03-04","ACTUAL",{"date":35,"type":21},"2025-02-22",{"date":37,"type":21},"2029-03-01",{"name":39,"class":40},"Zhejiang Provincial People's Hospital","OTHER"]